Aktis Oncology Unveils Key Insights at the 45th Annual TD Cowen Health Care Conference

Aktis Oncology CEO to Present at TD Cowen Health Care Conference

BOSTON, Feb. 25, 2025—Aktis Oncology, a company specializing in targeted radiopharmaceuticals, announced that Matthew roden, Ph.D., President and CEO, will participate in investor meetings at the 45th Annual TD Cowen Health Care Conference on Tuesday, March 4, 2025, in Boston.

Aktis Oncology: Pioneering Targeted Radiopharmaceuticals

Aktis Oncology is focused on “unlocking the breakthrough potential of targeted radiopharmaceuticals” for treating large patient populations with solutions beyond existing technologies. Their innovative approach specifically addresses cancers poorly served by current methods, marking a notable step forward in oncology.

Radiopharmaceuticals represent a cutting-edge area of cancer treatment, delivering radiation directly to cancer cells while minimizing damage to surrounding healthy tissue. This targeted approach can lead to improved outcomes and reduced side effects compared to customary radiation therapy.

Targeting Nectin-4 and Beyond

The company’s lead program zeroes in on Nectin-4, a tumor-associated antigen present in urothelial cancers and other solid tumors.Urothelial cancer,which includes bladder cancer,is a significant area of unmet medical need,highlighting the importance of Aktis’ work. According to the American Cancer Society, bladder cancer is estimated to account for over 83,000 new cases in 2024 alone. The company saeid their first of several pipeline programs targets Nectin-4, a tumor-associated antigen found in urothelial and other solid cancers.

• Nectin-4 as a Target: Nectin-4’s prevalence in various solid tumors makes it an attractive target for radiopharmaceutical therapies.
• Miniprotein radioconjugates: Aktis has developed a “proprietary miniprotein radioconjugate platform” to generate tumor targeting agents ideal for alpha radiopharmaceuticals.

The Miniprotein Advantage

Aktis’ miniprotein radioconjugates are engineered for maximal tumor penetration,internalization,and retention within cancer cells. These agents are designed to clear quickly from healthy tissues, thereby reducing side effects and enhancing anticancer activity. By improving drug delivery and minimizing off-target exposure, Aktis aims to improve both the efficacy and tolerability of cancer treatment. The company said they are “designed to maximize tumor killing through high penetration followed by internalization and retention in cancer cells.”

Strategic Collaboration with Eli Lilly and Company

In addition to it’s internal pipeline, Aktis Oncology has a collaboration with Eli Lilly and Company to develop novel radioconjugates outside of its proprietary pipeline. This collaboration underscores the potential of Aktis’ platform and its ability to drive innovation in radiopharmaceutical development. Partnerships between established pharmaceutical companies and innovative startups like Aktis are essential for accelerating the development of new cancer therapies.

Isotope-Agnostic Platform for Enhanced Visualization

The Aktis platform is isotope-agnostic, allowing clinicians to visualize and verify target engagement with imaging isotopes before using therapeutic radioisotopes. This capability for real-time monitoring of drug delivery sets Aktis apart,enabling the optimization of treatment strategies and personalization of care. Aktis is able to “visualize and verify target engagement with imaging isotopes prior to exposure to therapeutic radioisotopes.”

looking Ahead

Aktis Oncology’s presentation at the TD Cowen Health Care Conference marks a significant opportunity to showcase its progress and vision for the future of cancer treatment. With its innovative miniprotein radioconjugate platform and strategic collaborations, aktis is well-positioned to make a meaningful impact on the lives of patients with cancer. Keep an eye on Aktis Oncology as they push the boundaries of targeted radiopharmaceuticals and strive to bring more effective and personalized therapies to market.

For more facts and to follow Aktis Oncology’s journey, visit their website at www.aktisoncology.com.

What are the key advantages of Aktis Oncology’s miniprotein radioconjugate platform for cancer treatment?

Unlocking the Potential of Targeted Radiopharmaceuticals: an Interview with Aktis Oncology CEO Matthew Roden,Ph.D.

Welcome, Dr.Roden. Too kick things off, could you briefly introduce Aktis Oncology and its mission?

Matthew Roden: Thank you for having me. Aktis Oncology is a pioneering company focused on unlocking the breakthrough potential of targeted radiopharmaceuticals. our mission is to address cancers poorly served by existing methods, offering solutions for large patient populations with significant unmet needs.

Your lead program targets Nectin-4, a tumor-associated antigen present in various solid tumors. What makes Nectin-4 an attractive target?

Matthew Roden: Nectin-4’s prevalence in a wide range of solid tumors,including urothelial cancers,makes it an excellent target for our radiopharmaceutical therapies. Its high expression on cancer cells and low expression on normal tissues allows for a high degree of tumor specificity, which is crucial for minimizing side effects.

Aktis has developed a proprietary miniprotein radioconjugate platform.How does this technology improve cancer treatment?

Matthew Roden: Our miniprotein radioconjugates are engineered for maximal tumor penetration, internalization, and retention within cancer cells. This allows us to maximize tumor killing while minimizing off-target exposure, leading to improved efficacy and tolerability. Additionally, our platform is isotope-agnostic, enabling real-time monitoring of drug delivery and personalization of care.

You’ve recently announced a collaboration with Eli Lilly and company. How will this partnership accelerate the development of new cancer therapies?

Matthew Roden: Our collaboration with Lilly underscores the potential of our platform and allows us to expand our pipeline beyond our proprietary programs. By working together, we can accelerate the development of novel radioconjugates and bring more effective therapies to patients faster.

looking ahead, what excites you most about the future of Aktis Oncology and targeted radiopharmaceuticals?

Matthew Roden: I’m most excited about the potential to transform cancer treatment by delivering radiation directly to cancer cells.with our innovative platform and strategic collaborations, we’re well-positioned to make a meaningful impact on the lives of patients with cancer. The future of targeted radiopharmaceuticals is promising,and I believe Aktis is at the forefront of this revolution.

Thank you for your time, Dr. Roden. How can our readers learn more about Aktis Oncology and stay updated on your progress?

Matthew roden: thank you for having me. Readers can visit our website at www.aktisoncology.com to learn more about our company and follow our journey. We’re always sharing updates and insights on our latest research and developments.